Neuropsychological performance in young adults with cannabis use disorder DOI Creative Commons

Ayla Selamoglu,

Christelle Langley,

Rebecca Crean

и другие.

Journal of Psychopharmacology, Год журнала: 2021, Номер 35(11), С. 1349 - 1355

Опубликована: Окт. 25, 2021

Background and Aims: Cannabis is a commonly used recreational drug in young adults. The worldwide prevalence 18- to 25-year-olds approximately 35%. Significant differences cognitive performance have been reported previously for groups of cannabis users. However, the are often heterogeneous terms use. Here, we study daily users with confirmed diagnosis use disorder (CUD) examine on measures memory, executive function risky decision-making. Methods: Forty adult diagnosed CUD 20 healthy controls matched sex premorbid intelligence quotient (IQ) were included. neuropsychological battery implemented was designed measure multiple modes memory (visual, episodic working memory), decision-making other domains using subtests from Cambridge Neuropsychological Test Automated Battery (CANTAB). Results: Our results showed that perform significantly poorer tasks visual compared controls. In addition, functioning associated age onset. Conclusions: Further research required determine whether worse cognition or consequence Chronic heavy during critical period brain development may particularly negative impact cognition. Research into persistence how they relate functional outcomes such as academic/career required.

Язык: Английский

Cannabis use and cannabis use disorder DOI
Jason P. Connor, Daniel Stjepanović, Bernard Le Foll

и другие.

Nature Reviews Disease Primers, Год журнала: 2021, Номер 7(1)

Опубликована: Фев. 25, 2021

Язык: Английский

Процитировано

314
Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review DOI Open Access
Deborah S. Hasin, Claire Walsh

Journal of Clinical Medicine, Год журнала: 2020, Номер 10(1), С. 15 - 15

Опубликована: Дек. 23, 2020

Background: The landscape of attitudes, legal status and patterns use cannabis is rapidly changing in the United States elsewhere. Therefore, primary aim this narrative review to provide a concise overview literature on comorbidity disorder (CUD) with other substance psychiatric disorders, information accurately guide future directions for field. Methods: A PubMed was conducted studies relating use, CUD, co-occurring disorder. To an representative data, focused national-level, population-based work from National Epidemiologic Survey Alcohol Related Conditions (NESARC) Drug Use Health (NSDUH) surveys. Considering laws, recent (past five-year) were addressed. Results: strong body shows associations between CUD drug psychosis, mood anxiety personality disorders. strongest evidence potential causal relationship exists psychotic While some directionality results are inconsistent. Studies have established higher rates among those but little about specifics understood. Conclusions: Although general population increasingly perceives be harmless substance, empirical that associated both comorbid illness. However, there mixed regarding role etiology, course, prognosis across all categories Future research should expand existing representative, longitudinal order better understand acute long-term effects

Язык: Английский

Процитировано

90
The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use DOI Creative Commons
Valentina Lorenzetti, Chandni Hindocha, Kat Petrilli

и другие.

Addiction, Год журнала: 2021, Номер 117(6), С. 1510 - 1517

Опубликована: Сен. 30, 2021

Abstract Background The lack of an agreed international minimum approach to measuring cannabis use hinders the integration multidisciplinary evidence on psychosocial, neurocognitive, clinical and public health consequences use. Methods A group 25 expert researchers convened discuss a framework for standards measure globally in diverse settings. Results expert‐based consensus upon three‐layered hierarchical framework. Each layer—universal measures, detailed self‐report biological measures—reflected different research priorities standards, costs ease implementation. Additional work is needed develop valid precise assessments. Conclusions Consistent proposed across research, health, practice medical settings would facilitate harmonisation consumption, related harms approaches their mitigation.

Язык: Английский

Процитировано

71
Trends in the use of cannabis products in Canada and the USA, 2018 – 2020: Findings from the International Cannabis Policy Study DOI
David Hammond, Samantha Goodman, Elle Wadsworth

и другие.

International Journal of Drug Policy, Год журнала: 2022, Номер 105, С. 103716 - 103716

Опубликована: Май 23, 2022

Язык: Английский

Процитировано

69
Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults DOI Creative Commons
Jodi M. Gilman, Randi M. Schuster, Kevin Potter

и другие.

JAMA Network Open, Год журнала: 2022, Номер 5(3), С. e222106 - e222106

Опубликована: Март 18, 2022

Despite the legalization and widespread use of cannabis products for a variety medical concerns in US, there is not yet strong clinical literature to support such use. The risks benefits obtaining marijuana card common outcomes are largely unknown.

Язык: Английский

Процитировано

59
Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder DOI
Deepak Cyril D’Souza, Rajiv Radhakrishnan, Mika Naganawa

и другие.

Molecular Psychiatry, Год журнала: 2020, Номер 26(7), С. 3192 - 3200

Опубликована: Сен. 24, 2020

Язык: Английский

Процитировано

45
A social media intervention for cannabis use among emerging adults: Randomized controlled trial DOI Creative Commons
Erin E. Bonar, Jason E. Goldstick, Lyndsay Chapman

и другие.

Drug and Alcohol Dependence, Год журнала: 2022, Номер 232, С. 109345 - 109345

Опубликована: Фев. 3, 2022

Язык: Английский

Процитировано

24
Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review DOI
Rachel Lees, Lindsey A. Hines, Deepak Cyril D’Souza

и другие.

Psychological Medicine, Год журнала: 2021, Номер 51(3), С. 353 - 364

Опубликована: Фев. 1, 2021

Abstract Cannabis is the most widely used illicit drug worldwide, and it estimated that up to 30% of people who use cannabis will develop a disorder (CUD). Demand for treatment CUD increasing in almost every region world highly comorbid with mental disorders, where sustained can reduce compliance increase risk relapse. In this narrative review, we outline evidence psychosocial pharmacological strategies CUD, both alone when psychosis, anxiety or depression. Psychosocial treatments such as cognitive behavioural therapy, motivational enhancement therapy contingency management are currently effective strategy treating but limited benefit psychosis. Pharmacological targeting endocannabinoid system have potential withdrawal CUD. Mental health comorbidities including anxiety, depression psychosis hinder should be addressed provision clinical decision making global burden CUDs. Antipsychotic medication may decrease craving well psychotic symptoms patients Targeted feasible.

Язык: Английский

Процитировано

32
Pilot trial of a telehealth-delivered behavioral economic intervention promoting cannabis-free activities among adults with cannabis use disorder DOI Creative Commons
Lara N. Coughlin, Erin E. Bonar,

Joshua Wieringa

и другие.

Journal of Psychiatric Research, Год журнала: 2023, Номер 163, С. 202 - 210

Опубликована: Май 16, 2023

Язык: Английский

Процитировано

13
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol DOI Creative Commons
Anjali Bhardwaj,

Llew Mills,

Michael Doyle

и другие.

BMC Psychiatry, Год журнала: 2024, Номер 24(1)

Опубликована: Март 4, 2024

Abstract Background Cannabis use disorder (CUD) is increasingly common and contributes to a range of health social problems. Cannabidiol (CBD) non-intoxicating cannabinoid recognised for its anticonvulsant, anxiolytic antipsychotic effects with no habit-forming qualities. Results from Phase IIa randomised clinical trial suggest that treatment CBD four weeks reduced non-prescribed cannabis in people CUD. This study examines the efficacy, safety quality life longer-term patients moderate-to-severe Methods/Design A phase III multi-site, randomised, double-blinded, placebo controlled parallel design 12-week course placebo, follow-up at 24 after enrolment. Two hundred fifty adults CUD (target 20% Aboriginal), significant medical, psychiatric or other substance disorders seven drug alcohol clinics across NSW VIC, Australia will be enrolled. Participants administered daily dose either 4 mL (100 mg/mL) dispensed every 3-weeks. All participants receive four-sessions Cognitive Behavioural Therapy (CBT) based counselling. Primary endpoints are self-reported days analysis metabolites urine. Secondary include severity CUD, withdrawal severity, cravings, quantity use, motivation stop abstinence, medication safety, life, physical/mental health, cognitive functioning, patient satisfaction. Qualitative research interviews conducted Aboriginal explore their perspectives on treatment. Discussion Current psychosocial behavioural treatments indicate over 80% relapse within 1–6 months Pharmacological highly effective but there approved pharmacological promising candidate due potential efficacy this indication excellent profile. The anxiolytic, neuroprotective may have added benefits by reducing many mental impairments reported regular use. Trial registration Australian New Zealand Clinical Registry: ACTRN12623000526673 (Registered 19 May 2023).

Язык: Английский

Процитировано

5